X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

"If Washington isn’t careful, we might leave innovation behind"

By Robert Zirkelbach  |    June 24, 2019
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, a Voters for Cures advocate...   Read More

Ask About Adherence: Hepatitis C cures will save Medicaid $12 billion by 2022

By Katie Koziara  |    June 21, 2019
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study on the savings associated with new hepatitis C...   Read More

5 Ways to improve ICER’s value assessment framework

By Lauren Neves  |    June 20, 2019
The Institute for Clinical and Economic Review’s (ICER) recently made a call for suggestions and feedback on how to improve its value assessment framework and methods. We are a strong supporter of...   Read More

86 percent of AARP members support the Medicare rebate rule that AARP opposes

By Holly Campbell  |    June 12, 2019
Eighty-six percent of AARP members support the administration’s proposed rule to reform the rebate system in Medicare Part D, according to a nationwide Morning Consult survey commissioned by the...   Read More

Survey: AARP members support sharing medicine discounts with seniors

By Robert Zirkelbach  |    June 12, 2019
Earlier this year, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) released a proposed rule to reform the rebate system in Medicare Part D. In our current...   Read More

What you should know: Government arbitration is the wrong way to change Medicare

By Juliet Johnson  |    June 10, 2019
As Washington looks to make changes to Medicare, there are right ways and wrong ways to address the challenges patients face. In recent weeks, policymakers have discussed imposing government...   Read More

By the numbers: A look at the Part B International Pricing Index Model

By Nicole Longo  |    June 6, 2019
Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...   Read More

Assessing value top of mind at ISPOR 2019

By Samantha Dougherty  |    June 5, 2019
As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how...   Read More

New report finds 15 new oncology therapies launched last year

By Holly Campbell  |    June 5, 2019
A record 15 new oncology therapeutics launched in 2018 for 17 tumor types, according to IQVIA’s “Global Oncology Trends 2019” report. This progress includes a continued shift toward precision...   Read More

How the rebate rule would help reduce patients’ out-of-pocket costs

By Tom Wilbur  |    June 3, 2019
The Department of Health and Human Services recently proposed a rule that would encourage using discounts negotiated between biopharmaceutical manufacturers and Part D plans to reduce patients’...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates